company background image
NBRV

Nabriva Therapeutics NasdaqCM:NBRV Stock Report

Last Price

US$2.04

Market Cap

US$6.2m

7D

-6.2%

1Y

-89.5%

Updated

29 Nov, 2022

Data

Company Financials +
NBRV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

NBRV Stock Overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections.

Nabriva Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nabriva Therapeutics
Historical stock prices
Current Share PriceUS$2.04
52 Week HighUS$21.08
52 Week LowUS$1.81
Beta1.72
1 Month Change-16.43%
3 Month Change-50.56%
1 Year Change-89.55%
3 Year Change-99.58%
5 Year Change-99.86%
Change since IPO-99.94%

Recent News & Updates

Nabriva Therapeutics to effect 1-for-25 reverse stock split

Sep 15

Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta

Jul 18

Recent updates

Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022

Apr 04
Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022

Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts

Aug 11
Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts

We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation

Jul 22
We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation

When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?

Feb 16
When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?

Shareholder Returns

NBRVUS PharmaceuticalsUS Market
7D-6.2%0.5%-0.9%
1Y-89.5%13.0%-18.9%

Return vs Industry: NBRV underperformed the US Pharmaceuticals industry which returned 12.2% over the past year.

Return vs Market: NBRV underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is NBRV's price volatile compared to industry and market?
NBRV volatility
NBRV Average Weekly Movement20.8%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: NBRV is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: NBRV's weekly volatility has increased from 14% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200573Ted Schroederhttps://www.nabriva.com

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections.

Nabriva Therapeutics plc Fundamentals Summary

How do Nabriva Therapeutics's earnings and revenue compare to its market cap?
NBRV fundamental statistics
Market CapUS$6.24m
Earnings (TTM)-US$47.47m
Revenue (TTM)US$35.63m

0.2x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NBRV income statement (TTM)
RevenueUS$35.63m
Cost of RevenueUS$31.53m
Gross ProfitUS$4.10m
Other ExpensesUS$51.57m
Earnings-US$47.47m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-15.49
Gross Margin11.51%
Net Profit Margin-133.25%
Debt/Equity Ratio23.9%

How did NBRV perform over the long term?

See historical performance and comparison